December 5, 2018
Astellas Pharma announced on December 3 that its FLT3 inhibitor Xospata (gilteritinib) in a PI trial demonstrated a high response rate in previously untreated patients with FLT3 mutation-positive acute myeloid leukemia (AML) in combination with chemotherapy. The PI study evaluated...read more